Document is current
Any future updates will be listed below
-
Authors
Guo, Chengcheng
Yang, Qunying
Deng, Meiling
Qiu, Xiaoling
Wu, Shaoxiong
Du, Xiaojing
Sai, Ke
Dai, Ziyu
Chen, Zhenghe
Zhang, Ji
Lin, Fuhua
Ke, Chao
Xi, Shaoyan
Hu, Wanming
Zhou, Zhihuan
Li, Jiawei
Cao, Xi
Liao, Yixiang
Lv, Yanchun
Brown, Dennis
Langlands, John
Johnson, Gregory
Bacha, Jeffrey
Kwan, Claire
Kanekal, Sarath
Schwartz, Richard
Chen, Zhongping
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03050736 at ClinicalTrials.govDocuments that mention this clinical trial
VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study
https://doi.org/10.1007/s12672-025-04235-y
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (No. 82373440)
DelMar Pharmaceuticals Inc
Cancer Innovative Research Program of Sun Yat-sen University Cancer Center (CIRP-SYSUCC-PT13120101)
- License Information
-
More Information
Article History
Received: 23 July 2025
Accepted: 3 December 2025
First Online: 12 December 2025
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of Sun Yat‑sen University Cancer Center (B2016‑058‑01) on January 13, 2017, China, and registered with the ClinicalTrials.gov (NCT03050736) on February 13, 2017. Informed consent was obtained from all individual participants included in the study.
: The authors certify that they have obtained the appropriate participant consent form. In the forms, the participants have given their consent for the participants’ images and other clinical information to be reported in the journal. The participants understood that their names and initials would not be published and due efforts would be made to conceal their identity.
: This study was reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines.
: The authors declare no competing interests.
